---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-039986"
form_type: "8-K"
ticker: "DMII"
cik: "0002040475"
company_name: "Drugs Made In America Acquisition II Corp."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:42:58.939353+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DMIIU enters $1.4M convertible note agreement for de-SPAC financing; issues $300K interim note

## Summary
- Total financing commitment of $1.4M; $150K already received, $300K funded on March 30, 2026 as interim convertible note.
- Conversion at 35% discount to post-merger market value at investor's discretion; nine-month maturity.
- Proceeds used for audit, accounting, SEC, Nasdaq fees, legal costs, and transaction preparation.
- Existing sponsor non-performing; investor has right to acquire sponsor interests when legally permitted.
- Exclusivity period of six months to complete de-SPAC transaction.

## SEC filing metadata
- accession: 0001213900-26-039986
- form_type: 8-K
- ticker: DMII
- cik: 0002040475
- company_name: Drugs Made In America Acquisition II Corp.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/0001213900-26-039986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/ea0285112-8k_drugs2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-039986
- JSON: https://secwatch.observer/filing/0001213900-26-039986.json
- Plain text: https://secwatch.observer/filing/0001213900-26-039986.txt

## Source-grounded claims
- claim_id: ffe25265d1f383b097c9a48cc37fc17841e15ed7
  claim: Drugs Made In America Acquisition II Corp. incurred convertible notes of $300,000 with Alpha Multi Family Office at does not bear interest maturing nine months from the date of issuance.
  evidence_excerpt: In addition, on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the “ Second Note ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/0001213900-26-039986-index.htm
- claim_id: 502c7ea63c715cfeff70ea23eb2799375e3612d9
  claim: Drugs Made In America Acquisition II Corp. entered into Interim Convertible Note with Alpha Multi Family Office valued at $300,000 Interim Convertible Note, convertible with 35% discount (effective 2026-03-30).
  evidence_excerpt: on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the " Second Note ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/0001213900-26-039986-index.htm
- claim_id: 75d6b4cb9b136192d0bf8b8b15092a28e8053f8c
  claim: Drugs Made In America Acquisition II Corp. entered into Definitive Investment and Sponsor Transition Agreement with Alpha Multi Family Office valued at $1,400,000 Convertible Notes Financing (effective 2026-03-24).
  evidence_excerpt: Effective March 24, 2026, the Company and the Investor entered into the Definitive Investment and Sponsor Transition Agreement (the " Agreement ") for the Convertible Notes Financing, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/0001213900-26-039986-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.